Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

ARYx Series E Gets $30M To Fund Proof Of Concept

Feb. 8, 2006

By Jennifer Boggs

ARYx Series E Gets $30M To Fund Proof Of Concept

Feb. 8, 2006

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 10, 2025.
mRNA-based vaccine is immunogenic, protective in Lyme disease
BioWorld Science
Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because...
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Alzheon’s lead candidate misses a phase III in early Alzheimer’s
BioWorld
Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long...